Literature DB >> 2877016

Overview of effects of theophylline.

C G Persson.   

Abstract

Ever since xanthines were introduced into asthma therapy, more than 125 years ago, their therapeutic effectiveness has been explained as being due to extrapulmonary rather than, or in addition to, pulmonary drug actions. This article emphasizes that theophylline may have several potentially important effects in the lung. Theophylline relaxes the smooth muscle of large and small airways in humans and animals. Its relaxant effect is relatively independent of the type of mediator that constricts the airway. This suggests that functional antagonism, rather than specific pharmacologic mediator antagonism (e.g., adenosine antagonism), explains its bronchodilator effect. The consistent relaxant property of such xanthines as theophylline distinguishes these compounds from many other classes of established and experimental bronchodilator agents. Furthermore, many anti-inflammatory effects have been noted, suggesting that xanthines might be considered as prophylactic agents. Theophylline may not only attenuate the activity of stationary and blood-borne pulmonary inflammatory cells; it may also exert an anti-inflammatory action by directly affecting targets such as the epithelial lining (increasing the mucociliary transport rate) and the microvasculature (possibly reducing plasma exudation). The experimental anti-inflammatory pharmacology of theophylline is compatible with the observation that theophylline inhibits late pulmonary reactions in patients with atopic asthma and in sensitized animals challenged with allergen. The mechanism(s) of action behind the pulmonary actions of theophylline has not been assessed (neither phosphodiesterase inhibition nor adenosine antagonism may be involved). Central nervous system, gastroesophageal, renal, and metabolic actions of theophylline are briefly reviewed. Headache, nausea, and the relaxation of the lower esophageal sphincter can perhaps be classified as nonexcitatory and inhibitory effects in which the mechanism(s) of action is unknown.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877016     DOI: 10.1016/0091-6749(86)90061-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

1.  Bioavailability of oral isbufylline in rabbits.

Authors:  A Celardo; G Dell'Elba; M Bonati
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

2.  Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers.

Authors:  M C Braat; R E Jonkers; E H Bel; C J Van Boxtel
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

4.  Tracheal relaxation from combinations of xanthines and of a beta 2-receptor agonist and xanthines.

Authors:  C G Persson; B Gustafsson
Journal:  Lung       Date:  1986       Impact factor: 2.584

Review 5.  Clinical expression of bronchial hyperreactivity in children.

Authors:  C W Bierman; G G Shapiro
Journal:  Clin Rev Allergy       Date:  1989

Review 6.  Drug therapy approaches in the treatment of acute severe asthma in hospitalised children.

Authors:  L K DeNicola; M O Gayle; K V Blake
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.

Authors:  J Cortijo; J Bou; J Beleta; I Cardelús; J Llenas; E Morcillo; R W Gristwood
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

Review 9.  Oral theophylline for chronic obstructive pulmonary disease.

Authors:  F S Ram; P W Jones; A A Castro; J A De Brito; A N Atallah; Y Lacasse; R Mazzini; R Goldstein; S Cendon
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs.

Authors:  K H Banner; C P Page
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.